R&D channel feed – Endpoints News

R&D channel feed

Expanded syndicate puts Avelas onto the PoC track with $20M cancer tech round

9 years ago

Cerulean crashes after lead nano drug flubs its second PhII cancer study

9 years ago

Protocols: Indivior claims PhIII success, points to 2017 FDA OK; InVivo touts another patient response in spinal study

9 years ago

Controversial patient deaths in CAR-T study spur a class action suit against Juno

9 years ago

RIP: After burning through $463M, StemCells’ corpse is bought out for the public shell

9 years ago

The $140,672,343 man: Why does Brent Saunders have the richest golden parachute in biopharma?

9 years ago

Split the pot? Radius shows its osteoporosis cards in final blockbuster match with Amgen

9 years ago

The ‘don’t eat me’ antidote: GlaxoSmithKline, Roche and Novo back $86M startup in high-stakes CD47 showdown

9 years ago

Hopes fading, OncoGenex acknowledges a PhIII flop for cancer drug

9 years ago

Sorrento's new pain player Scintilla going solo after $200M buyout deal

9 years ago

Vertex shutters a PhIII cystic fibrosis combo study, shares slip

9 years ago

Will some pent-up deal pressure amp up a biotech rally?

9 years ago

Protocols: Bavarian collaborates with BMS on lung cancer study; Eleven completes Roche deal; Intellia chief anticipates new CRISPR tweaks

9 years ago

Facing questions on patient deaths, Aurinia shares crater in wake of lupus study

9 years ago

FDA to Chiasma on their Phase III rejection: Come up with a better plan next time

9 years ago

Working to get its pain R&D strategy back on track, AcelRx steps closer to an FDA pitch

9 years ago

Zymeworks bags a protein engineering platform as it preps for an IPO

9 years ago

AstraZeneca gets a boost from durvalumab PhIII chatter as pipeline wear and tear starts to show

9 years ago

Biotech venture champion Bill Maris is exiting GV. What’s next?

9 years ago

Start small, think big: Genmab racks up a bispecific development deal with HIV specialist Gilead

9 years ago

Protagonist’s IPO option delivers a $90M payoff for early-stage peptide work

9 years ago

The Brent Saunders way: Allergan pays $95M for its next stepping stone to a bigger pipeline

9 years ago

Another old drug looks for a second coming at the FDA, this time for Duchenne MD

9 years ago

Microbiome upstart Vedanta teams up with NYU Langone scientist on checkpoint drugs

9 years ago

First page Previous page 322 323 324325326 327 328 Next page Last page